● 本报记者 刘丽靓 在国企改革深化提升行动攻坚收官的关键阶段，国有资本布局优化与结构调整正加速破局。数据显示， 2025年1至11月，全国国企并购重组事件累计达265件，同比增长14.22%。从中央到地方，随着一系列 指向明确、措施精准的政策接连出台，一批重大项目密集签约落地，一场以专业化整合为主线、 向"新"而行的国资深度变革正向纵深推进，持续为构建新发展格局汇聚新动能。 提升国有资本配置运营效率 12月1日，国务院国资委主任张玉卓在《人民日报》发表署名文章提出，要加强战略性、专业化重组， 围绕强化功能使命、提升规模效益，加大力度合并"同类项"，避免重复建设和无序竞争。 在央企重组深入推进的同时，地方国企改革亦呈加速态势。知本咨询数据显示，2025年1至11月，地方 国企完成并购重组事件56件，同比增长36.59%，增速显著高于央企。 各地结合自身资源禀赋与发展阶段，探索出特色鲜明的改革路径。12月4日，湖北省国资委主任陈忠表 示，坚持"三线并进"，强化资本运作，以战略性并购重组为重要手段，加快省属实体产业转型升级。 同日，四川省委金融办会同四川证监局联合印发《四川省推进企业上市和上市公司并购重组三年行动 ...

Group 1 - The article discusses the political crisis in South Korea triggered by the emergency martial law declared by former President Yoon Suk-yeol, which has led to significant political changes and public unrest [3][4]. - President Lee Jae-myung has proposed establishing December 3 as "National Sovereignty Day" to commemorate the peaceful resolution of the crisis, emphasizing the need for accountability for those involved in the martial law declaration [3][4]. - The article highlights the ongoing legal troubles faced by Yoon Suk-yeol and his associates, with multiple charges against them, including allegations of treason and obstruction of justice [5][6][7]. Group 2 - The South Korean economy is experiencing challenges, with a projected growth rate of only 2% for 2024, raising concerns about the impact of the political crisis on domestic demand [8][9]. - The Bank of Korea reported a GDP contraction of 0.1% in Q1 2024, marking the first decline since Q4 2020, primarily due to weak construction investment and consumer spending [9][10]. - In Q2 2024, the economy showed signs of recovery with a 0.7% quarter-on-quarter growth, driven by strong performance in the manufacturing sector, particularly in semiconductors and electronics [10][11]. - The government has implemented various economic measures to stimulate growth, including support for AI, biotechnology, and cultural industries, alongside a supplementary budget to stabilize the financial market [10][11]. - The third quarter saw the fastest economic growth in nearly a year, with a 1.3% quarter-on-quarter increase in GDP, attributed to strong exports and government stimulus [10][11].

Core Viewpoint - The partnership between Africa and China is not just a vision but an active construction of a community with a shared future, emphasizing mutual respect, co-creation, and tangible social impact in the modernization process [1]. Group 1: Innovation and Cooperation - In 2024, Kenya and China will launch over 20 technology cooperation projects in fields such as agriculture, health, space science, and digital transformation [1]. - The upcoming China-Africa Innovation Cooperation and Development Forum in 2025 will focus on the theme "Hand in Hand for Innovative Cooperation, Promoting the Modernization Process" [1]. Group 2: Institutional Development - The plan prioritizes the establishment of a China-Africa Innovation Cooperation Center and the expansion of joint laboratories, research centers, and technology parks [2]. - Strengthening capacity building and personnel exchanges in key sustainable development areas such as modern agriculture, biodiversity conservation, climate resilience, public health, and spatial information technology is a focus [2]. Group 3: Digital and Green Development - The partnership aims to bridge the digital divide and accelerate digital transformation, with green development being a key area of cooperation, including clean energy projects and innovations in energy storage technology [2]. - Joint laboratories, incubation centers, and innovation programs supported by China-Africa cooperation are accelerating the application and commercialization of new technologies, creating jobs, and improving community life [2]. Group 4: Investment in Technology Ecosystem - African countries need to increase investment in the technology and innovation ecosystem, enhancing collaboration between industry, academia, and research to turn research breakthroughs into practical solutions [2]. - Strong partnerships are required in fields such as artificial intelligence, biotechnology, clean energy, and digital infrastructure to create sustainable development models [2].

兴银理财党委委员、总裁 汪圣明 党的二十届四中全会再次强调大力发展科技金融、绿色金融、普惠金融、养老金融、数字金融"五篇大 文章"，为金融业的高质量发展指明航向。其中，科技金融居于首位，不仅凸显了其战略重要性，更意 味着它将成为贯通其他"文章"的核心脉络与强大引擎。作为连接资金与产业的桥梁，理财公司深刻认识 到，以科技金融之力，赋能"五篇大文章"的协同书写，是我们肩负的时代使命与发展的历史机遇。 建立健全组织架构，确保战略有效落地。兴银理财成立"五篇大文章"工作领导小组及科技金融工作专 班，建立多部门协同联动的高效运作机制。领导小组由公司主要负责人牵头，各业务部门负责人共同参 与，定期研究部署科技金融工作的重大事项。工作专班则负责具体执行，由投资、研究、风控等部门的 业务骨干组成，确保各项措施落到实处。通过制定详细的科技金融工作计划、绘制清晰的"施工 图"与"时间表"，公司将顶层设计转化为具体行动，建立起从目标设定、过程管理到结果评估的完整闭 环。 强化政策学习和行业研究，保持战略前瞻性。工作专班定期组织专题会议学习最新政策精神，深入研讨 科技金融发展趋势。兴银理财建立了政策解读和研究机制，及时把握国家在科技 ...

Core Viewpoint - Baoyi Pharmaceutical Co., Ltd. plans to issue H-shares on the Hong Kong Stock Exchange, aiming to raise approximately HKD 1 billion with a maximum share price of HKD 26.38 per share, and the listing is expected on December 10, 2025 [1][3]. Group 1: Company Overview - Baoyi Pharmaceutical was established in December 2019 and is located in Baoshan District, Shanghai, with a registered capital of approximately CNY 57.61 million [3]. - The company focuses on four main areas: (i) large-volume subcutaneous delivery, (ii) antibody-mediated autoimmune diseases, (iii) assisted reproduction, and (iv) recombinant biopharmaceuticals, with a pipeline of 12 self-developed products [4][5]. Group 2: Financial Performance - The projected revenues for Baoyi Pharmaceutical are approximately CNY 6.93 million for 2023, CNY 6.16 million for 2024, and CNY 41.99 million for the first half of 2025, with corresponding gross profits of CNY 6.78 million, CNY 5.02 million, and CNY 41.73 million [5][6]. - The net losses are expected to be CNY 160.4 million for 2023, CNY 364.4 million for 2024, and CNY 183.1 million for the first half of 2025 [6][7]. Group 3: Investment and Partnerships - Baoyi Pharmaceutical has secured three cornerstone investors, raising HKD 200.6 million, including Anke Biological Hong Kong and Guotai Junan Securities [3]. - The company has established technical service and supply agreements with antibody drug companies and signed an exclusive sales agency agreement with Anke Biological for the commercialization of its core product SJ02 in Greater China [7]. Group 4: Production Capacity - The company has built a GMP-compliant production facility in Shanghai, covering approximately 63,000 square meters, capable of meeting the commercial production needs for SJ02 and clinical production for several candidate drugs [8].

Core Viewpoint - The new materials industry is crucial for supporting modern industrial systems and achieving high-level technological self-reliance, with significant strategic importance for building a strong manufacturing and quality nation [2]. Industry Background and Development Situation - During the 14th Five-Year Plan, China's new materials industry saw continuous growth, with total output value exceeding 8.2 trillion yuan and an average annual growth rate of over 12% [4]. - Achievements include breakthroughs in ultra-high-strength steel, high-performance carbon fiber, semiconductor silicon wafers, and key materials for lithium-ion batteries [4]. - Challenges remain in high-end materials and the need for improved self-sufficiency in core processes and equipment [4]. Overall Requirements - The guiding ideology emphasizes innovation-driven development, demand-oriented approaches, and green low-carbon principles [7]. - Key principles include self-reliance through innovation, application-driven demand, and collaboration among enterprises [9]. Development Goals (by 2030) - Comprehensive security capability for key strategic materials to exceed 80% [11]. - Global competitiveness in innovation, with over 500 key core technologies to be developed [11]. - Establishment of over 20 internationally leading new materials industrial clusters [11]. Key Development Directions - Advanced basic materials include ultra-high-strength automotive steel and high-performance aluminum alloys [13][14]. - Strategic materials focus on high-temperature alloys and advanced semiconductor materials [18][20]. - New energy materials target high-energy-density battery materials and efficient photovoltaic materials [21][22]. Key Tasks and Major Projects - Focus on urgent new materials needed in critical application areas such as aerospace, new energy vehicles, and electronic information [28]. - Specific targets include high-temperature alloys for aerospace engines and high-energy-density battery materials for electric vehicles [29][33]. Collaborative Innovation System - Establish a collaborative innovation system centered on enterprises, integrating industry, academia, and research [53]. - Plans to build national-level new materials innovation platforms and increase funding for research and development [54]. Market Cultivation for Key New Materials - Implement insurance compensation mechanisms for the first application of key new materials to encourage market adoption [58]. - Develop a standard system for new materials to ensure product quality and market order [59]. Breakthroughs in Key Processes and Equipment - Focus on overcoming bottlenecks in key processes and specialized equipment for new materials production [64]. - Plans to support the development of over 80 key processes and equipment technologies [67].

新华社北京11月30日电 《中共中央关于制定国民经济和社会发展第十五个五年规划的建议》提 出："强化科学研究、技术开发原始创新导向"。这是全面增强自主创新能力，加快推进高水平科技自立 自强的重要举措。 科技强国的基本要素之一就是拥有强大的基础研究和原始创新能力，持续产出重大原创性、颠覆性科技 成果。历史发展进程表明，世界科技强国都是科学基础雄厚的国家，在重要科技领域处于领先行列，特 别是在解决人类面临的重大挑战、基本科学问题上，能够开辟新的领域方向、构建新的科学理论体系。 只有掌握原创基础理论、底层技术原理，才能筑牢科技创新根基和底座。实现高水平科技自立自强、建 设科技强国，必须把基础研究摆在突出位置，从源头和底层解决关键核心技术问题。只有进一步强化原 始创新导向，才能让科技创新之树更加枝繁叶茂。 世界百年变局加速演进，科技成为大国博弈主战场。集成电路、生物科技等是竞争最激烈的领域，也是 我国"卡脖子"问题突出的领域。只有瞄准世界科技前沿，下好"先手棋"，打好基础、储备长远，不断取 得重大原创性成果，才能筑牢国家安全底座，夯实发展的根基。 当前，科学研究向极宏观拓展、向极微观深入、向极端条件迈进、向极综合交叉 ...

我们将这本新书的部分内容整理了出来，分享给各位读者，希望对您有所启发。 01 必须回答却被忽视的问题 一个国家的债务及其增长是否存在极限？ 作为桥水基金的创始人，瑞·达利欧对投资原则和周期方面有着独到见解。这些见解被深入应用于实际投资 工作中，带领桥水避开了2008年金融危机等大大小小各式危机，并为投资者创造了巨额收益，具有极高的 现实意义和借鉴意义，也深得政策决策者、商界领袖和各领域专家学者的认同。 今年6月，瑞·达利欧在X上发布长文，介绍其新书《国家如何破产：大周期》的核心观点。这位全球宏观投 资者用50余年投资经验，再次系统揭示了国家如何走向债务危机：不是突然爆发，而是一个可以量化、可 监测的"大债务周期"，最终演变为系统性失控，就像"经济心脏病发作"。 在《国家如何破产：大周期》中，达利欧不仅对过去500年的世界历史进行了系统的梳理和研究，还从中提 炼出了一套理论框架，用以解释国家兴衰的周期性规律。达利欧告诫投资者："要想做好投资，就不能只关 注市场。" 如果政府债务增长未能放缓，那么利率及其影响将会如何？ 一个拥有主要储备货币的大国（比如美国）是否会破产？倘若会，那又将引发怎样的连锁反应？ 是否存在 ...

朋友们，有没有觉得最近钱越来越难赚了，花钱却越来越谨慎？ 别急，一场关乎你我钱包的重磅会议即将敲定2026年的经济走向。 每年12月召开的中央经济工作会议，被称为中国经济的"风向标"，今年尤其特殊。 2025年是"十四五"规划收官之年，也是"十五五"规划的谋划起点。 这场会议不仅要总结过去五年重大项目的进展，比如光刻机国产化到了哪一步，还要明确明年经济怎么干、钱往哪里流。 从房贷利率、就业机会到养老育儿补贴，会议释放的信号将直接影响你的月供、工资和消费选择。 历史经验告诉我们，比如2016年会议首次提出"房住不炒"，精准预示了房价拐点。 经济目标的实现，需要产业层面的支撑。 会议上，新兴产业和传统行业的转型路径会成为讨论重点。 人工智能、新能源、生物技术等领域的扶持政策如何细化，传统制造业如何升级，这些议题都关联着未来的就业市场和投资风口。 2025年8月的数据显示，中国人工智能企业数量已突破5000家，平均每天新增2家，相关专利占全球总量的60%。 这些具体进展，需要在会议上评估效果。 眼下，内需不足、楼市调整、外部压力三重挑战叠加，会议如何出招，值得每个普通人盯紧。 2025年中央经济工作会议的特殊性，首 ...

Core Viewpoint - The company, as the first IVD listed enterprise on the Sci-Tech Innovation Board, is transitioning from in vitro diagnostics to biopharmaceuticals, aligning with the national bio-manufacturing strategy and focusing on long-term growth through global expansion and innovation in the biopharmaceutical sector [2][4]. Group 1: Industry Trends and Company Strategy - Biomanufacturing is recognized as a strategic emerging industry for the next decade, with biopharmaceuticals being a key battleground due to high technical barriers [4]. - The company's expansion from in vitro diagnostics to biopharmaceuticals is seen as a natural extension of its core competencies in biotechnology, emphasizing the interconnectedness of diagnostic and therapeutic technologies [4][5]. - The company has made significant investments in basic research, resulting in publications in top-tier journals and the establishment of a solid R&D framework [4]. Group 2: Innovation and Product Development - The company adheres to the "uniqueness and firstness" principle in its innovation pipeline, focusing on unmet clinical needs and developing products such as the world's first antibody drug for myocardial infarction [8][10]. - The company has developed advanced technologies in liver cancer early screening, which are widely used in high-risk populations and included in expert consensus guidelines [8]. - The company aims to achieve the goal of "Chinese scientists discovering first, Chinese enterprises transforming first, and Chinese hospitals conducting clinical trials first" in its drug development efforts [8]. Group 3: Global Market Expansion - The company has initiated overseas expansion since 2019, achieving over 600 foreign certifications and establishing a presence in Southeast Asia, South Asia, the Middle East, and Latin America [10]. - The company positions its products as high-quality and cost-effective alternatives to those from developed countries, aiming to provide better healthcare options for developing nations [10]. - The company emphasizes the importance of international certifications and understanding local market needs as key factors for successful overseas operations [10].